Invited Speakers



Professor Sir John Burn

Professor Sir John Burn obtained an MD with distinction, a first class honours degree in human genetics from Newcastle University, where he has been Professor of Clinical Genetics since 1991 and a consultant specialist since 1984.

He led the regional NHS Genetics Service for 20 years and helped to create the Centre for Life which houses an education and science centre alongside the Institute of Genetic Medicine and Northgene Ltd, the identity testing company he launched in 1995.

He chairs DNA device company QuantuMDx.

He was knighted in 2010, chosen as one of the first 20 'local heroes' to have a brass plaque on Newcastle Quayside in 2014.

He received the Living North award in 2015 for services to the North East 2000 – 2015. He is also Executive Chairman of the international organisation, the Human Variome Project, which seeks to share knowledge of genetic variation for clinical benefit. In 2017, John became Chairman of the Newcastle upon Tyne Hospitals NHS Foundation Trust. 

Please click here to view the programme.


Professor Dr Evelien Dekker

Professor Dr Evelien Dekker is a board-qualified gastroenterologist at the Department of Gastroenterology & Hepatology of the Academic Medical Centre at the University of Amsterdam. She graduated from the same university, and obtained her PhD in 1996 at the same university. She received her training in Internal Medicine and Gastroenterology at the Academic Medical Centre. Dr Dekker joined the AMC-staff in 2005 and is head of the multidisciplinary clinic for hereditary colorectal cancer and medical director of an expert colonoscopy centre at the AMC. She is actively involved in the national screening program for colorectal cancer since more than 10 years, for which she has been awarded a honourable "Pearl" by ZonMW.

Her research focuses on quality and new techniques in colonoscopy, population screening and surveillance for colorectal cancer, and treatment and surveillance of familial cancer and polyposis syndromes. She was appointed as a professor in GI Oncology at the University of Amsterdam in 2013, and has supervised 25 students for a PhD-thesis. She has co-authored over 250 scientific articles and has chaired and participated in several national and international guidelines.

Please click here to view the programme.


Dr Michael Hall

Dr Michael Hall is the Interim Chair of the Department of Clinical Genetics at Fox Chase Cancer Center (FCCC), Philadelphia PA and is an Associate Professor of Medicine in the FCCC gastrointestinal oncology and cancer prevention and control programs. He is a trained health services researcher and clinical cancer geneticist.

He received his undergraduate and medical degrees from Columbia University in New York City.

He went on to complete an internal medicine residency at Harvard's Brigham and Women's hospital and a fellowship in Hematology/Oncology at the University of Chicago where he established a clinical and research focus in GI cancers and genetic risk and earned a Master's degree in health services research.

His current research includes the study of patient attitudes and preferences toward hereditary risk assessment and testing, novel methods to communicate of high risk information within families, and collaborative research in gene discovery and large testing database analyses. He is the recipient of individual and collaborative research funding from the Chemotherapy Foundation, the Greenwall Foundation, the American Cancer Society, and the National Cancer Institute.

Please click here to view the programme.

Professor Magnus von Knebel Doeberitz, MD

Magnus von Knebel Doeberitz is Professor of Molecular Oncology and Medical Director of the Department of Applied Tumor Biology, Institute of Pathology of the University of Heidelberg. He is also head of the Clinical Cooperation Unit G105 of the German Cancer Research Center and is affiliated with the Molecular Medicine Partner Unit of the European Molecular Biology Laboratory (EMBL).

After graduating from medical school in 1984 he spent his post doc in the laboratory of the later Nobel laureate Harald zur Hausen at the German Cancer Research Center. In 2001 he was appointed as Medical Director of the Department of Applied Tumour Biology at the Institute of Pathology, University of Heidelberg.

He coauthored more than 280 peer-reviewed articles. He is associate editor of the International Journal of Cancer and member of the editorial boards of various other prestigious oncology journals.

He received numerous scientific awards and served as founder, advisor and board member of several biotech companies.

Please click here to view the programme.

Heather Hampel, MS, LGC

Heather Hampel completed her Bachelor of Science degree in Molecular Genetics at the Ohio State University in 1993.   She attained her Master's degree in Human Genetics from Sarah Lawrence College in 1995.  She received certification from the American Board of Genetic Counseling in 1996.  She worked as a cancer genetic counselor at Memorial Sloan- Kettering Cancer Center before moving to The Ohio State University Comprehensive Cancer Center (OSUCCC) in 1997. 

Currently, Heather is a Professor in the Department of Internal Medicine and Associate Director of the Division of Human Genetics.  She is also the Associate Director of Biospecimen Research for the OSUCCC.

She was the study coordinator for the Columbus-area Lynch syndrome study which determined the frequency of Lynch syndrome among newly diagnosed patients with these cancers.  This study culminated in first author publications in the New England Journal of Medicine in May of 2005, Cancer Research in August of 2006, and the Journal of Clinical Oncology in December of 2008. 

She is now the PI of the Ohio Colorectal Cancer Prevention Initiative which is screening colorectal cancer patients from 50 hospitals throughout the state for hereditary cancer syndromes. The first major publication from that study showing that 16% of early-onset colorectal cancers are hereditary was published in 2017 in JAMA Oncology.

Heather Hampel was the Region IV Representative on the Board of Directors of the National Society of Genetic Counselors in 2003-4. She was on the Board of Directors for the American Board of Genetic Counseling from 2006-2011, serving as President in 2009 and 2010. She was elected to the Steering Committee member of the National Colorectal Cancer Roundtable in 2016. She has been on the Council of the Collaborative Group of the Americas on Inherited Colorectal Cancer since 2016 and is currently the President.

Please click here to view the programme.



Dr James Church

James Church was born and raised in New Zealand, attending Auckland Medical School and then entering surgical training.

In 1983 he began a colorectal fellowship at the Cleveland Clinic and in 1989 he joined the Staff. He retired in 2016 and is currently Contract Staff. He held the Victor W. Fazio Chair and recently stepped down as Director of the Sanford R. Weiss Center for Hereditary Colorectal Neoplasia. He has been Chairman of the Leeds Castle Polyposis Group and the International Collaborative Group on HNPCC and founded the Collaborative Group of the Americas for Inherited Colorectal Cancer.

Dr Church was Co-Editor of Diseases of the Colon and Rectum for 10 years, Vice President of ASCRS and received the Distinguished Alumni Award from the University of Auckland. He is a Fellow of the American Surgical Association and several other Professional Societies. The sole author of 2 textbooks, editor of several, and author or co-author of over 370 peer-reviewed articles.

Please click here to view the programme.


Professor Sue Clark

Sue Clark is a Consultant Colorectal Surgeon at St Mark's Hospital, Harrow, UK and Professor of Practice (Colorectal Surgery) at Imperial College, London. She is also Director of the St Mark's Hospital Polyposis Registry and Dean of the St Mark's Academic Institute. She was an elected member of InSiGHT council 2009-13, and now leads the InSiGHT secretariat as Administrative Officer.

Since completing her thesis on desmoids in FAP, she has continued active research in the polyposis syndromes, supervising several PhDs and authoring over 50 papers in the field. She is a member of the Royal College of Surgeons of England Commission on the Future of Surgery, with the remit of Genomic Medicine.

Please click here to view the programme.


Dr Ian Frayling

Ian qualified in Clinical Medicine at Cambridge. After initial training in all branches of pathology, he studied DNA repair for his PhD. He is the only Genetic Pathologist in NHS service, at the Institute of Medical Genetics, Cardiff.

Ian was the Family Cancer Clinic Research Fellow at St Mark's Hospital, 1993-1998.  He now concentrates on variant interpretation, genotype-phenotype correlations and systematic testing of incident cancers to identify hereditary cases.  He is a Fellow of the Royal College of Pathologists, a UK National External Quality Assessor of MMR IHC, an Honorary Senior Clinical Research Fellow at Cardiff University, and a Visiting CI at Cancer Council New South Wales.  He is a co-author on the upcoming 5th Edition of the WHO/IARC Classification of Tumours "Blue Books" series.  (

Ian is also a member of InSiGHT Council and the Variant Interpretation Committee; a member of CGAICC; the steering group of the Prospective Lynch Syndrome Database; an Honorary Medical Adviser to Lynch Syndrome UK; and Treasurer of the UK Cancer Genetics Group, inter alia.

In 2017, Ian was conferred with Honorary Fellowship of the Faculty of Pathology of the Royal College of Physicians of Ireland in recognition of his outstanding lifetime contribution to the practice of pathology and received the Association of Clinical Pathologists' Dyke Foundation Medal.  He will deliver the Goudie Medal lecture in January 2019 at the Pathological Society's Winter Meeting.

Please click here to view the programme.


Professor Parry Guilford

Professor Parry Guilford is Director of the Cancer Genetics Laboratory and the Centre for Translational Cancer Research (Te Aho Matatū) at the University of Otago. He is a co-founder of the publically listed biotechnology company Pacific Edge Ltd and a Deputy Director of the Healthier Lives National Science Challenge. His current research interests include the genetics of inherited and sporadic cancers, in particular stomach cancer. Other active research areas are the development of genomic-based diagnostic tools for early cancer detection and personalised medicine.  

Please click here to view the programme.


Dr Matthew Kalady

Dr. Matthew Kalady is a Professor of Surgery at Cleveland Clinic in Cleveland, Ohio. He graduated cum laude from Harvard College and received his medical doctorate from Duke University.  He completed his general surgery training at Duke University Medical Center and subsequently completed a colorectal surgery fellowship at Cleveland Clinic. He holds the James Church MD and Edward DeBartolo Jr. Family Endowed Chair in Colorectal Surgery, is the Co-Director of the Cleveland Clinic Comprehensive Colorectal Cancer Program, and is the Director of the Sanford R.Weiss, MD, Center for Hereditary Colorectal Neoplasia. 

He is on the editorial board of Diseases of the Colon and Rectum, and Annals of Surgical Oncology. He also has an NIH/NCI-funded basic science research laboratory focusing on colorectal cancer genetics.  His main clinical interests are colorectal cancer, hereditary syndromes, and minimally invasive surgery.  

Please click here to view the programme.


Professor Gabriela Moeslein

Professor Moeslein is Professor of Surgery and Director of the Center for Hereditary Tumours, Helios University Hospital. She chaired the biennial InSiGHT meeting in 2009 in Düsseldorf. She is a founding member of the IMRC (International Mismatch Repair Consortium) and external advisor of InSiGHT for the CFR (Cancer Family Registries) She is also a founding member of the German Consortium for HNPCC and Steering Committee member.

In September 2017 she has been appointed General Secretary of ESCP. She is founding Director of the EHTG (European Hereditary Tumor Group) Her research activities focus on hereditary predisposition to cancer, prophylactic surgery for hereditary conditions, ileoanal and Kock pouches and chemoprevention. 

Please click here to view the programme.


John Windsor

John Windsor holds a personal chair in Surgery at the University of Auckland and Is Yeoh Ghim Sen Professor at National University of Singapore. 

Fellow American Surgical Association, James IV Association of Surgeons and Royal Society of New Zealand.  He is an HBP/Upper GI surgeon at the Auckland City Hospital, Director of the Centre for Surgical and Translational Research (encompassing the Applied Surgery and Metabolism Laboratory, Surgical Trials Unit, Surgical Engineering Laboratory and Global Surgery Group), Assistant Director of MedTech Centre of Research Excellence and national chair of HBP Tumour Stream.  His primary clinical and research interests are pancreatic diseases.

Please click here to view the programme.





Rachel Cook
Conference Innovators
P: +64 9 525 2464

insight19 logo